tirzepatide cvot results cardiovascular event risk assessment: a pre-specified meta-analysis SURPASS-CVOT — Leicester Diabetes Centre

For more information on this regulatory update, please refer to the FDAs official statement: FDA's official statement We appreciate your understanding and patience as we navigate this regulatory adjustment

Many patients report subtle or noticeable changes in food preferences within the first month of starting treatment, ranging from decreased cravings for sweet or fatty foods to altered salt perception

Pancreatitis risk both carry a warning

If you suspect a pen has been frozen, throw it away in a sharps container

Safety & side effects Common side effects The most common side effects are gastrointestinal, nausea, diarrhea, vomiting, and constipation, usually mild to moderate and most likely while your dose is being increased